SABCS 2021: Updates in HER2+ Breast Cancer

Sara A. Hurvitz, MD, provides perspective on key research that was presented during the 2021 SABCS in HER2-positive metastatic breast cancer.

John Cole, MD, discusses the next steps with tucatinib in HER2-positive breast cancer.

Joanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.

Sara A. Hurvitz, MD, discusses the clinical implications of the ongoing phase 2 SUMMIT trial in HER2-mutated breast cancer.

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.